Q4 & Year-End 2022
Results & 2023 Outlook
January 25, 2023
Executing our Strategy to Accelerate Growth
with Strong Commercial Capabilities
Consumer Inspired | Superior | |
Innovation | In-Market Execution | |
Iconic Digital-First | Revenue Growth | |
Brands | Management | |
OUR PURPOSE
Better Care for a Better world
Ac
hieve
d
B
a
l
a
n
ce
d
a
n
d
S
u | a | le |
stain | b |
s | |
le | |
Sa |
2 | ||||||||
2 | ||||||||
0 | ||||||||
2 | ||||||||
in | ||||||||
h | ||||||||
t | ||||||||
w | ||||||||
ro | ||||||||
G |
NET SALES | ORGANIC SALES GROWTH1 | GROSS MARGIN2 | ADJUSTED |
OPERATING MARGIN3 | |||
2022 | 5B | 5 | +270 | +200 | |||
Q4 | $ | % | |||||
Flat YoY | Excludes FX -500 bps | BPS YoY 32.8% | BPS YoY 14.3% | ||||
FY | $20B | 7% | -80 | -160 | |||
2022 | +4% YoY | Excludes FX -400 bps | BPS YoY 30.8% | BPS YoY 13.0% | |||
Healthy Organic Growth1 on 1-Year and 3-Year Average | 2022 | 3 Year Average ['19-'22] | ||
Total Company | Personal Care |
+7% | +7% |
+6% | |
+4% |
2022 Overview
Grew portfolio of iconic brands
Grew or held market share in ~50% of markets
Innovation, advertising investments, commercial execution drove growth momentum
Price net of input cost and currencies impact turning positive in the second half of 2023
Consumer Tissue | KC-Professional |
+7% | +9% | |
+3% | +1% | |
Sequentially improved gross and operating margins as pricing continued to build and input costs eased off peak levels in Q4
Revenue growth management actions strengthened QoQ
Continued margin recovery while investing
Delivered $1.7B in dividends and share repurchases
2023 Outlook4
Sustainable Growth and Margin Recovery
- Maintain topline growth momentum with pipeline of innovation, commercial agility and disciplined investment
- Gross margin improvement to fuel continued growth investments
2 - 4% | -200 bps | +MSD - HSD | Gross | +100 bps | 2 - 6% |
ORGANIC | SALES IMPACT | OPERATING | Margin | ADVERTISING | EPS GROWTH5 |
SALES GROWTH1 | from FX | PROFIT GROWTH5 | Recovery | investment to fuel | with higher |
driven by strong | Operating margin | sales growth and | interest rates, | ||
Revenue growth | |||||
pricing, market | up ~80 bps at the | scale innovation | effective tax rate | ||
share gains and | midpoint | management, | |||
expansion | cost discipline, | ||||
in growth markets | innovation offset | ||||
input/mfg cost | |||||
increases | |||||
Capital Allocation Aligned with Value Creation Priorities
Dividend Per Share | Invest in Our Business |
(declared)
$4.64
Building Future Capabilities
+5%
$2.96 | CAGR | Grow the Dividend |
Share Repurchases
2012 | 2022 | Value Creating M&A |
- Organic net sales describes the impact of changes in volume, net selling prices and product mix on net sales. Changes in foreign currency exchange rates, acquisitions and exited businesses are excluded from organic growth.
- Compared to 2021 adjusted gross margin.
- Non-GAAPmeasure. Please see the company's Q4 2022 earnings press release for more information and a reconciliation to comparable measures under GAAP. The earnings release can be found on our website at www.kimberly-clark.comunder the Investors section, or via the following link: www.kimberly-clark.com/investors.
- Certain matters contained in this Infographic concerning the outlook, anticipated financial and operating results, growth initiatives and the anticipated cost savings from the company's FORCE program constitute forward-looking statements and are based upon management's expectations and beliefs concerning future events impacting the company. Many factors outside our control, including the war in Ukraine (including the related responses of consumers, customers and suppliers as well as sanctions issued by the U.S., the European Union, Russia or other countries), pandemics (including the ongoing COVID-19 outbreak and the related responses of governments, consumers, customers, suppliers and employees), epidemics, the prices and availability of our raw materials, supply chain disruptions, failure to realize the expected benefits or synergies from our acquisition and disposition activity (including our pending agreement to sell our Neve tissue brand and associated assets in Brazil), changes in customer preferences, severe weather conditions, government trade or similar regulatory actions, potential competitive pressures on selling prices for our products, energy costs, fluctuations in foreign currency exchange rates, our ability to maintain key customer relationships, as well as general economic and political conditions globally and in the markets in which we do business, could affect the realization of these estimates. There can be no assurance that these future events will occur as anticipated or that the company's results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them. For a description of certain factors that could cause the company's future results to differ from those expressed in any such forward-looking statements, see Item 1A entitled "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2021.
- Compared to 2022 adjusted results.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Kimberly-Clark Corporation published this content on 25 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 January 2023 13:07:04 UTC.